Highlights in bladder cancer from ASCO GU 2021

Parminder Singh, MD, Mayo Clinic Hospital, Phoenix, AZ, shares his highlights in bladder cancer treatment from ASCO GU 2021. In particular, he discusses updates from the EV-301 trial (NCT03474107) investigating the use of enfortumab vedotin for patients with locally advanced or metastatic urothelial carcinoma. Dr Singh also talks about the Phase II/III QUILT-3.032 trial (NCT03022825) of a IL-15 superagonist, N-803, in BCG unresponsive non muscle invasive bladder cancer. This interview took place during the 2021 Genitourinary Cancers Symposium.